FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969625103> ?p ?o ?g. }

• W2969625103 endingPage "260" @default.
• W2969625103 startingPage "1" @default.
• W2969625103 abstract "Background Over 44,000 women are diagnosed with breast cancer annually in the UK. The research comprised three workstreams (WSs) focused on older women. Maximising survival WS1 – to identify the role of older women’s and surgeons’ preferences in cancer treatment decisions and whether comorbidity or fitness for surgery has an impact on survival. Minimising complications WS2 – to assess multifrequency bioimpedance (BEA) compared with perometry in identifying women predisposed to develop lymphoedema after axillary node clearance (ANC) surgery. WS3 – to assess, in women at risk of lymphoedema, whether or not applying compression garments prevents the onset of lymphoedema. Design WS1 – a prospective, consecutive cohort of surgical consultations with women aged ≥ 70 years with operable breast cancer. Interviews and questionnaire surveys of surgeons’ and women’s perceptions of responsibility for treatment decisions (Controlled Preference Score), effects related to survival and secondary outcomes. WS2 – women undergoing ANC for cancer in 21 UK centres underwent baseline and subsequent BEA, and perometer arm measurements and quality-of-life (QoL) assessments. WS3 – a randomised controlled trial testing standard versus applying graduated compression garments to the affected arm, for 1 year, in WS2 patients developing arm swelling. Setting Breast outpatient clinics in hospitals with specialist lymphoedema clinics. Participants WS1 – patients aged ≥ 70 years with newly diagnosed, operable, invasive breast cancer. WS2 – women with node-positive cancer scheduled to undergo ANC. WS3 – WS2 participants developing a 4–9% increase in arm volume. Interventions WS1 – observational study. WS2 – observational study. WS3 – application of graduated compression garments to affected arm, compared with standard management, for 1 year. Outcomes WS1 – self-report and clinically assessed health, QoL, complications and survival. WS2 – perometer and bioimpedance spectroscopy (BIS) measurements, QoL and health utility; and sensitivity and specificity of BIS for detecting lymphoedema compared with perometer arm measurements; in addition, a health economics assessment was performed. WS3 – time to the development of lymphoedema [≥ 10% relative arm-volume increase (RAVI)] from randomisation. Results WS1 – overall, 910 women were recruited, but numbers in the substudies differ depending on consent/eligibility. In a study of patient/surgeon choice, 83.0% [95% confidence interval (CI) 80.4% to 85.6%] had surgery. Adjusting for health and choice, only women aged > 85 years had reduced odds of surgery [odds ratio (OR) 0.18, 95%CI 0.07 to 0.44]. Patient role in treatment decisions made no difference to receipt of surgery. A qualitative study of women who did not have surgery identified three groups: ‘patient declined’, ‘patient considered’ and ‘surgeon decided’. In a survival substudy, adjusting for tumour stage, comorbidity and functional status, women undergoing surgery had one-third the hazard of dying from cancer. Serious complications from surgery were low and not predicted by older age. In a substudy of the effect of surgical decision-making on HRQoL, 59 (26%) received preferred treatment decision-making style. In multivariate analyses, change in HRQoL was associated neither with congruence ( p = 0.133) nor with receipt of surgery ( p = 0.841). In a substudy of receipt of chemotherapy in women aged ≥ 65 years, adjusting for tumour characteristics, health measures and choice, women aged ≥ 75 years had reduced odds of chemotherapy (OR 0.06, 95%CI 0.02 to 0.16). WS2 – lymphoedema by 24 months was detected in 21.4% of women by perometry (24.4% sleeve application) and in 39.4% by BIS. Perometer and BIS measurements correlated at 6 months ( r = 0.61). Specificity for sleeve application was greater for perometry (94% CI 93% to 96%) at 24 months, as was a positive predictive value of 59% (95% CI 48% to 68%). Lymphoedema diagnosis reduced QoL scores. Sleeve application in the absence of RAVI of > 9% did not improve QoL or symptoms. A composite definition of lymphoedema was developed, comprising a 9% cut-off point for perometer and self-reported considerable swelling. Diagnostic accuracy was ≥ 94% at 6, 12 and 24 months. WS3 – the PLACE (Prevention of Lymphoedema After Clearance of External compression) trial recruited 143 patients, but recruitment was slow and closed early on the advice of the Independent Data Monitoring Committee. A qualitative substudy identified a number of barriers to recruitment. Conclusions Half of older patients felt that they influenced decisions about their treatment. No relationship between decision preference being fulfilled and HRQoL in elderly patients diagnosed with cancer occurred, and older age did not predict complications. Primary surgery reduced the hazard of dying of cancer by two-thirds, independent of age, health and tumour characteristics. Women aged ≥ 75 years have reduced odds of receiving chemotherapy. Lymphoedema (along with a BMI of > 30 kg/m 2 , cigarette smoking and chemotherapy) reduces QoL. Changes in arm volume of > 9% predicted lymphoedema requiring and benefiting from sleeve application. The PLACE trial qualitative work provides a number of insights into problems of recruitment that were specific to this trial (stigma of compression garments) but that are also generalisable to other RCTs. Limitations Both WS1 and WS2 were large, multicentre, UK cohort, observational studies. The WS3 PLACE trial has not reported yet but closed with approximately half of the patients originally planned. Future work Research producing objective measures for sleeve prescription in the NHS is required. Trial registration Current Controlled Trials ISRCTN48880939. Funding This project was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research programme and will be published in full in Programme Grants for Applied Research ; Vol. 7, No. 5. See the NIHR Journals Library website for further project information. Additional support for WS1 came from a Breast Cancer Campaign Grant and a NIHR Postdoctoral Fellowship. ImpediMed (Carslbad, CA, USA; www.impedimed.com ) provided bioimpedance L-Dex ® machines and electrodes for the study and Sigvaris provided the external compression garments free of charge for the (PLACE) trial." @default.
• W2969625103 created "2019-08-29" @default.
• W2969625103 creator A5038261855 @default.
• W2969625103 creator A5039277732 @default.
• W2969625103 creator A5041481134 @default.
• W2969625103 creator A5047809966 @default.
• W2969625103 creator A5049004669 @default.
• W2969625103 creator A5066870932 @default.
• W2969625103 creator A5068798579 @default.
• W2969625103 creator A5071040536 @default.
• W2969625103 creator A5074723186 @default.
• W2969625103 date "2019-08-01" @default.
• W2969625103 modified "2023-10-11" @default.
• W2969625103 title "Individualising breast cancer treatment to improve survival and minimise complications in older women: a research programme including the PLACE RCT" @default.
• W2969625103 cites W1534453636 @default.
• W2969625103 cites W1543894487 @default.
• W2969625103 cites W1591159023 @default.
• W2969625103 cites W1857905445 @default.
• W2969625103 cites W1966972930 @default.
• W2969625103 cites W1975280119 @default.
• W2969625103 cites W1989362621 @default.
• W2969625103 cites W1990323979 @default.
• W2969625103 cites W1998545062 @default.
• W2969625103 cites W2002861424 @default.
• W2969625103 cites W2007069804 @default.
• W2969625103 cites W2009692809 @default.
• W2969625103 cites W2011524302 @default.
• W2969625103 cites W2012202415 @default.
• W2969625103 cites W2015805367 @default.
• W2969625103 cites W2017258870 @default.
• W2969625103 cites W2019311984 @default.
• W2969625103 cites W2025991594 @default.
• W2969625103 cites W2026096564 @default.
• W2969625103 cites W2030354154 @default.
• W2969625103 cites W2033912701 @default.
• W2969625103 cites W2034625941 @default.
• W2969625103 cites W2037797670 @default.
• W2969625103 cites W2044826725 @default.
• W2969625103 cites W2053567347 @default.
• W2969625103 cites W2054422745 @default.
• W2969625103 cites W2059116066 @default.
• W2969625103 cites W2069103088 @default.
• W2969625103 cites W2100395035 @default.
• W2969625103 cites W2101893979 @default.
• W2969625103 cites W2118249259 @default.
• W2969625103 cites W2119402730 @default.
• W2969625103 cites W2128614409 @default.
• W2969625103 cites W2133124363 @default.
• W2969625103 cites W2134774645 @default.
• W2969625103 cites W2141453541 @default.
• W2969625103 cites W2143712591 @default.
• W2969625103 cites W2144833893 @default.
• W2969625103 cites W2149007458 @default.
• W2969625103 cites W2154460443 @default.
• W2969625103 cites W2154929223 @default.
• W2969625103 cites W2158208054 @default.
• W2969625103 cites W2159435435 @default.
• W2969625103 cites W2161911084 @default.
• W2969625103 cites W2164777277 @default.
• W2969625103 cites W2576869589 @default.
• W2969625103 cites W1969412504 @default.
• W2969625103 doi "https://doi.org/10.3310/pgfar07050" @default.
• W2969625103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31436943" @default.
• W2969625103 hasPublicationYear "2019" @default.
• W2969625103 type Work @default.
• W2969625103 sameAs 2969625103 @default.
• W2969625103 citedByCount "0" @default.
• W2969625103 crossrefType "journal-article" @default.
• W2969625103 hasAuthorship W2969625103A5038261855 @default.
• W2969625103 hasAuthorship W2969625103A5039277732 @default.
• W2969625103 hasAuthorship W2969625103A5041481134 @default.
• W2969625103 hasAuthorship W2969625103A5047809966 @default.
• W2969625103 hasAuthorship W2969625103A5049004669 @default.
• W2969625103 hasAuthorship W2969625103A5066870932 @default.
• W2969625103 hasAuthorship W2969625103A5068798579 @default.
• W2969625103 hasAuthorship W2969625103A5071040536 @default.
• W2969625103 hasAuthorship W2969625103A5074723186 @default.
• W2969625103 hasBestOaLocation W29696251031 @default.
• W2969625103 hasConcept C121608353 @default.
• W2969625103 hasConcept C126322002 @default.
• W2969625103 hasConcept C141071460 @default.
• W2969625103 hasConcept C159110408 @default.
• W2969625103 hasConcept C168563851 @default.
• W2969625103 hasConcept C1862650 @default.
• W2969625103 hasConcept C201903717 @default.
• W2969625103 hasConcept C23131810 @default.
• W2969625103 hasConcept C27415008 @default.
• W2969625103 hasConcept C2779951463 @default.
• W2969625103 hasConcept C2781392513 @default.
• W2969625103 hasConcept C3020110884 @default.
• W2969625103 hasConcept C530470458 @default.
• W2969625103 hasConcept C71924100 @default.
• W2969625103 hasConcept C72563966 @default.
• W2969625103 hasConceptScore W2969625103C121608353 @default.
• W2969625103 hasConceptScore W2969625103C126322002 @default.
• W2969625103 hasConceptScore W2969625103C141071460 @default.
• W2969625103 hasConceptScore W2969625103C159110408 @default.
• W2969625103 hasConceptScore W2969625103C168563851 @default.

• next